AI-driven drug discovery for age-related lung fibrosis and its clinical translation. Offers context on scientific rationale, strategy, and geroscience potential.
Key Takeaways
- Insilico initiated a Phase III clinical program for rentosertib
- Phase IIa GENESIS-IPF showed 60 mg dosing increased mean FVC by 98.4 mL
- TNIK was nominated via Insilico's AI biology platforms and shows senomorphic activity